Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ISBISTER, G. K
Right arrow Articles by ITO, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by ISBISTER, G. K
Right arrow Articles by ITO, S.
Related Collections
Right arrow Drugs: obstetrics and gynecology
Right arrow Perinatal
Arch Dis Child Fetal Neonatal Ed 2001;85:F145 ( September )

Letters to the editor

Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome?

The first 150 words of the full text of this article appear below.

EDITOR---We would like to comment on the article "Neonatal paroxetine withdrawal syndrome" in the March 2001 issue of the journal.1 The authors describe what they have called "neonatal paroxetine withdrawal syndrome". However the syndrome reported in the 4 neonates appears to be more consistent with serotonin toxicity, rather than withdrawal of paroxetine.

The literature to date contains one large series,2 two similar case reports with fluoxetine3 4 and two case reports with paroxetine.5 6

In the fluoxetine cases the syndrome was not described as a withdrawal phenomenon. In the first, a neonate born to a mother on fluoxetine had jitteriness, irritability, tachypnoea, temperature instability, tremors, increased muscle tone, and a hyperactive Moro reflex.3 All except the last of these are clinical features seen in serotonin toxicity in adults using selective serotonin uptake inhibitors (SSRIs) therapeutically or in overdose.7 8 The neonate in this case had fluoxetine levels that were measurable initially and which . . . [Full text of this article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health